MidFirst Bank’s Neurocrine Biosciences NBIX Stock Holding History

MidFirst Bank’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.53K	Hold	15	–	–	﹤0.01%	670
2026 Q1	$1.98K	Sell	15 -1,224	-99%	-$162K	﹤0.01%	685
2025 Q4	$2.13K	Buy	+1,239	New	+$179K	﹤0.01%	679

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MidFirst Bank's NBIX Position: Q2 2026 in Review

MidFirst Bank held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 15 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #670.

MidFirst Bank first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 624 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

MidFirst Bank held 15 shares of Neurocrine Biosciences worth $2.53K as of Q2 2026.
MidFirst Bank left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of MidFirst Bank's portfolio in Q2 2026, its #670 holding.
MidFirst Bank first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
624 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on MidFirst Bank's 13F filing for Q2 2026, filed 7 Aug 2026.